{"id":11667,"date":"2014-05-05T15:25:16","date_gmt":"2014-05-05T15:25:16","guid":{"rendered":"http:\/\/cardiophile.org\/?p=11667"},"modified":"2014-05-05T15:25:16","modified_gmt":"2014-05-05T15:25:16","slug":"treatment-of-progeria-with-farnesylation-inhibitors","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/treatment-of-progeria-with-farnesylation-inhibitors\/","title":{"rendered":"Treatment of Progeria with Farnesylation Inhibitors"},"content":{"rendered":"

Treatment of Progeria with Farnesylation Inhibitors<\/span><\/h2>\n

Hutchinson-Gilford Progeria Syndrome (HGPS) is a genetic disorder characterized by premature aging and the affected children die of myocardial infarction or cerebrovascular accidents at a young age of around thirteen years. HGPS is caused by a single gene mutation in the LMNA gene encoding for lamin A\/C, component of nuclear lamina. This deletion mutation causes accumulation of an abnormal protein known as progerin. Progerin which is improperly farnesylated and truncated leads to abnormal nuclear scaffolding. Hence farnesyl transferase inhibitors have been used in the treatment of progeria. In a study published in the Circulation [1] farnesylation inhibitors increased the survival by about 1.6 years compared to the usual survival of around fourteen and a half years.<\/p>\n

Reference<\/strong><\/span><\/p>\n

    \n
  1. Leslie B Gordon, Joe Massaro, Ralph B D’Agostino Sr, Susan E Campbell, Joan Brazier, W Ted Brown, Monica E Kleinman, Mark W Kieran, Progeria Clinical Trials Collaborative. Impact of Farnesylation Inhibitors on Survival in Hutchinson-Gilford Progeria Syndrome<\/a>. Circulation. 2014 Jul 1;130(1):27-34.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Treatment of Progeria with Farnesylation Inhibitors Hutchinson-Gilford Progeria Syndrome (HGPS) is a genetic disorder characterized by premature aging and the affected children die of myocardial infarction or cerebrovascular accidents at a young age of around thirteen years. HGPS is caused by a single gene mutation in the LMNA gene encoding for lamin A\/C, component of […]<\/p>\n","protected":false},"author":1,"featured_media":34367,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[9],"tags":[85,726,1454,1683,1729,2029,2197,2198,2521,3038,3039],"class_list":["post-11667","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general","tag-abnormal-nuclear-scaffolding","tag-cerebrovascular-accidents-in-children","tag-farnesylation-inhibitors","tag-hgps","tag-hutchinson-gilford-progeria-syndrome","tag-lamin-ac","tag-lmna","tag-lmna-gene","tag-myocardial-infarction-in-children","tag-progeria","tag-progerin"],"yoast_head":"\nTreatment of Progeria with Farnesylation Inhibitors - All About Cardiovascular System and Disorders<\/title>\n<meta name=\"description\" content=\"Treatment of Progeria with Farnesylation Inhibitors improved survival by about 1.6 years, over the usual survival of around 14.5 years.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/treatment-of-progeria-with-farnesylation-inhibitors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Treatment of Progeria with Farnesylation Inhibitors - All About Cardiovascular System and Disorders\" \/>\n<meta property=\"og:description\" content=\"Treatment of Progeria with Farnesylation Inhibitors improved survival by about 1.6 years, over the usual survival of around 14.5 years.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/treatment-of-progeria-with-farnesylation-inhibitors\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2014-05-05T15:25:16+00:00\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/treatment-of-progeria-with-farnesylation-inhibitors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/treatment-of-progeria-with-farnesylation-inhibitors\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Treatment of Progeria with Farnesylation Inhibitors\",\"datePublished\":\"2014-05-05T15:25:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/treatment-of-progeria-with-farnesylation-inhibitors\\\/\"},\"wordCount\":169,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/treatment-of-progeria-with-farnesylation-inhibitors\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"abnormal nuclear scaffolding\",\"cerebrovascular accidents in children\",\"Farnesylation Inhibitors\",\"HGPS\",\"Hutchinson-Gilford Progeria Syndrome\",\"lamin A\\\/C\",\"LMNA\",\"LMNA gene\",\"myocardial infarction in children\",\"Progeria\",\"Progerin\"],\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/treatment-of-progeria-with-farnesylation-inhibitors\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/treatment-of-progeria-with-farnesylation-inhibitors\\\/\",\"name\":\"Treatment of Progeria with Farnesylation Inhibitors - All About Cardiovascular System and Disorders\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/treatment-of-progeria-with-farnesylation-inhibitors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/treatment-of-progeria-with-farnesylation-inhibitors\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2014-05-05T15:25:16+00:00\",\"description\":\"Treatment of Progeria with Farnesylation Inhibitors improved survival by about 1.6 years, over the usual survival of around 14.5 years.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/treatment-of-progeria-with-farnesylation-inhibitors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/treatment-of-progeria-with-farnesylation-inhibitors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/treatment-of-progeria-with-farnesylation-inhibitors\\\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/treatment-of-progeria-with-farnesylation-inhibitors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Treatment of Progeria with Farnesylation Inhibitors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Treatment of Progeria with Farnesylation Inhibitors - All About Cardiovascular System and Disorders","description":"Treatment of Progeria with Farnesylation Inhibitors improved survival by about 1.6 years, over the usual survival of around 14.5 years.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/treatment-of-progeria-with-farnesylation-inhibitors\/","og_locale":"en_US","og_type":"article","og_title":"Treatment of Progeria with Farnesylation Inhibitors - All About Cardiovascular System and Disorders","og_description":"Treatment of Progeria with Farnesylation Inhibitors improved survival by about 1.6 years, over the usual survival of around 14.5 years.","og_url":"https:\/\/johnsonfrancis.org\/professional\/treatment-of-progeria-with-farnesylation-inhibitors\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2014-05-05T15:25:16+00:00","author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/treatment-of-progeria-with-farnesylation-inhibitors\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/treatment-of-progeria-with-farnesylation-inhibitors\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Treatment of Progeria with Farnesylation Inhibitors","datePublished":"2014-05-05T15:25:16+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/treatment-of-progeria-with-farnesylation-inhibitors\/"},"wordCount":169,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/treatment-of-progeria-with-farnesylation-inhibitors\/#primaryimage"},"thumbnailUrl":"","keywords":["abnormal nuclear scaffolding","cerebrovascular accidents in children","Farnesylation Inhibitors","HGPS","Hutchinson-Gilford Progeria Syndrome","lamin A\/C","LMNA","LMNA gene","myocardial infarction in children","Progeria","Progerin"],"articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/treatment-of-progeria-with-farnesylation-inhibitors\/","url":"https:\/\/johnsonfrancis.org\/professional\/treatment-of-progeria-with-farnesylation-inhibitors\/","name":"Treatment of Progeria with Farnesylation Inhibitors - All About Cardiovascular System and Disorders","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/treatment-of-progeria-with-farnesylation-inhibitors\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/treatment-of-progeria-with-farnesylation-inhibitors\/#primaryimage"},"thumbnailUrl":"","datePublished":"2014-05-05T15:25:16+00:00","description":"Treatment of Progeria with Farnesylation Inhibitors improved survival by about 1.6 years, over the usual survival of around 14.5 years.","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/treatment-of-progeria-with-farnesylation-inhibitors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/treatment-of-progeria-with-farnesylation-inhibitors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/treatment-of-progeria-with-farnesylation-inhibitors\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/treatment-of-progeria-with-farnesylation-inhibitors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Treatment of Progeria with Farnesylation Inhibitors"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/11667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=11667"}],"version-history":[{"count":0,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/11667\/revisions"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=11667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=11667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=11667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}